Borgman Anne Elizabeth 4

What Happened
Anne Elizabeth Borgman, a director of NextCure, Inc. (NXTC), received a derivative equity award on June 18, 2026: an option covering 2,340 shares reported at $0.00 on the Form 4 (award/acquisition, code A). This filing records the grant of the option rather than a cash purchase or open-market sale.

Key Details

• Transaction date: 2026-06-18; Form 4 filed: 2026-06-22 (filed within the two-business-day window).
• Amount: 2,340 shares (derivative option) at reported price $0.00 (grant/reporting value on Form 4).
• Shares owned after transaction: Not specified in the provided filing details.
• Footnote: The option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders.
• Transaction type: Award/option grant (code A), part of director compensation (not an open-market buy or sell).

Context
This is a compensation-related option grant to a director. Such awards are routine for board members and do not by themselves indicate a personal cash investment or sale. The footnote clarifies the vesting schedule; the award becomes exercisable in full by mid-2027 assuming the vesting condition is met.